Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

Robert E. Lanford, Elisabeth S. Hildebrandt-Eriksen, Andreas Petri, Robert Persson, Morten Lindow, Martin E. Munk, Sakari Kauppinen, Henrik Rum

Research output: Contribution to journalArticlepeer-review

1385 Scopus citations

Abstract

The liver-expressed microRNA-122 (miR-122) is essential for hepatitis C virus (HCV) RNA accumulation in cultured liver cells, but its potential as a target for antiviral intervention has not been assessed. We found that treatment of chronically infected chimpanzees with a locked nucleic acid (LNA)-modified oligonucleotide (SPC3649) complementary to miR-122 leads to long-lasting suppression of HCV viremia, with no evidence of viral resistance or side effects in the treated animals. Furthermore, transcriptome and histological analyses of liver biopsies demonstrated derepression of target mRNAs with miR-122 seed sites, down-regulation of interferon-regulated genes, and improvement of HCV-induced liver pathology. The prolonged virological response to SPC3649 treatment without HCV rebound holds promise of a new antiviral therapy with a high barrier to resistance.

Original languageEnglish (US)
Pages (from-to)198-201
Number of pages4
JournalScience
Volume327
Issue number5962
DOIs
StatePublished - 2010
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection'. Together they form a unique fingerprint.

Cite this